Anzeige
Meldung des Tages: Kupfer-Engpass trifft jetzt auf starke Rohstoffhausse

GSK Glaxo Smith Kline Aktie (ADR) News

Aktie
WKN:  A3DMHS ISIN:  US37733W2044 US-Symbol:  GSK Branche:  Pharmazeutika Land:  Großbritannien
41,40 €
-0,2 €
-0,48%
07:31:35 Uhr
Depot/Watchlist
Marktkapitalisierung *
85,06 Mrd. €
Streubesitz
80,79%
KGV
8,56
Dividende
0,42 $
Dividendenrendite
0,85%
Faktor
0.5
Originalaktie
GB00BN7SWP63

GSK Glaxo Smith Kline Aktie (ADR) News

03.09.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK PR Newswire
27.08.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK PR Newswire
22.08.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK PR Newswire
16.08.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK PR Newswire
11.08.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK PR Newswire
31.07.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK PR Newswire
27.07.25 - PR Newswire
Hengrui Pharma and GSK enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
Hengrui Pharma and GSK enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology PR Newswire
27.07.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc - GSK PR Newswire
02.06.25 - PR Newswire
Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million
Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million PR Newswire
07.04.25 - PR Newswire
Shareholders that lost money on GSK plc(GSK) Urged to Join Class Action - Contact The Gross Law Firm to Learn More
Shareholders that lost money on GSK plc(GSK) Urged to Join Class Action - Contact The Gross Law Firm to Learn More PR Newswire
07.04.25 - PR Newswire
GSK Investors Have Opportunity to Lead GSK plc Securities Fraud Lawsuit with the Schall Law Firm
GSK Investors Have Opportunity to Lead GSK plc Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
04.04.25 - PR Newswire
Contact Levi & Korsinsky by April 7, 2025 Deadline to Join Class Action Against GSK plc(GSK)
Contact Levi & Korsinsky by April 7, 2025 Deadline to Join Class Action Against GSK plc(GSK) PR Newswire
03.04.25 - PR Newswire
Shareholders that lost money on GSK plc(GSK) should contact The Gross Law Firm about pending Class Action - GSK
Shareholders that lost money on GSK plc(GSK) should contact The Gross Law Firm about pending Class Action - GSK PR Newswire
02.04.25 - PR Newswire
GSK Deadline: GSK Investors Have Opportunity to Lead GSK plc Securities Fraud Lawsuit
GSK Deadline: GSK Investors Have Opportunity to Lead GSK plc Securities Fraud Lawsuit PR Newswire
02.04.25 - PR Newswire
GSK plc. (GSK) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
GSK plc. (GSK) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire
02.04.25 - PR Newswire
GSK Investors Have Opportunity to Lead GSK plc Securities Fraud Lawsuit with the Schall Law Firm
GSK Investors Have Opportunity to Lead GSK plc Securities Fraud Lawsuit with the Schall Law Firm PR Newswire
01.04.25 - PR Newswire
GSK plc. (GSK) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
GSK plc. (GSK) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire
01.04.25 - PR Newswire
Shareholders of GSK plc Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - GSK
Shareholders of GSK plc Should Contact Levi & Korsinsky Before April 7, 2025 to Discuss Your Rights - GSK PR Newswire
31.03.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GSK plc of Class Action Lawsuit and Upcoming Deadlines - GSK
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GSK plc of Class Action Lawsuit and Upcoming Deadlines - GSK PR Newswire
31.03.25 - PR Newswire
Class Action Filed Against GSK plc (GSK) Seeking Recovery for Investors - Contact The Gross Law Firm
Class Action Filed Against GSK plc (GSK) Seeking Recovery for Investors - Contact The Gross Law Firm PR Newswire

Newssuche

Videos

newspaper
22.01.26 -5,56%
Trading Insights vom 22.01.26
Preisschock bei Erdgas! Was sind die Gründe, wie geht man damit um? Gold auf neuem Allzeithoch: wie ... Mehr »
Anzeige

Aktie im Fokus

GOLD-AUSBRUCH
GMV Minerals
0,187 €
+13,3%
GMV Minerals Chart
Von der PEA zum Milliarden-Potenzial
Mehr zur Aktie »